AccueilZYME • NASDAQ
add
Zymeworks
12,96 $
Après la clôture :(0,00 %)0,00
12,96 $
Fermé : 2 mai, 16:01:02 UTC−4 · USD · NASDAQ · Clause de non-responsabilité
Dernière clôture
12,88 $
Variation sur la journée
12,90 $ - 13,23 $
Plage sur l'année
8,21 $ - 17,70 $
Capitalisation boursière
901,72 M USD
Volume moyen
732,02 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 31,03 M | 83,33 % |
Charges d'exploitation | 16,18 M | 9,19 % |
Résultat net | -23,51 M | -62,31 % |
Marge bénéficiaire nette | -75,75 | 11,47 % |
Bénéfice par action | -0,31 | -55,00 % |
EBITDA | -19,22 M | 8,11 % |
Taux d'imposition effectif | -32,12 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 225,78 M | -39,68 % |
Total des actifs | 463,09 M | -20,28 % |
Total du passif | 124,32 M | 7,11 % |
Total des capitaux propres | 338,77 M | — |
Actions en circulation | 69,58 M | — |
Ratio cours/valeur comptable | 2,62 | — |
Rentabilité des actifs | -11,69 % | — |
Retour sur capitaux | -14,92 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | déc. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -23,51 M | -62,31 % |
Trésorerie (opérations) | -41,51 M | -397,46 % |
Trésorerie (invest.) | -6,21 M | -364,77 % |
Trésorerie (financement) | -8,64 M | -117,08 % |
Variation nette en trésorerie | -56,25 M | -188,97 % |
Flux de trésorerie dispo. | -29,00 M | -312,85 % |
À propos
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver,
British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital that year. In May 2017, Zymeworks held an IPO on the Toronto Stock Exchange, raising $59 million. This was the largest Canadian biotech IPO in more than a decade. By alphabetical order, Zymeworks is the last company on the Toronto Stock Exchange.
In May 2019, Zymeworks announced that GSK has expanded its 2016 licensing and collaboration agreement for the research, development and commercialization of bispecific antibodies across multiple disease areas. The extended agreement has meant that GSK can have access to Zymeworks' heavy-light chain pairing technology, which enables the development of bispecific and multifunctional therapeutics. Wikipedia
Date de fondation
2003
Siège social
Site Web
Employés
283
